Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病NMOSD
A group of inflammatory conditions that mainly affect the optic nerves and the spinal cord. Most people with it have antibodies to the protein aquaporin-4; some do not.
Definition adapted from MeSH (US National Library of Medicine), Wingerchuk 2015
Listed in China's first national rare-disease catalogue (2018, no. 81). National Health Commission 国卫医发〔2018〕10号
- hospitals in mainland China
- 67
- cities
- 29
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 27% of the world's English-language research papers on neuromyelitis optica spectrum disorder, 2021–2025 (21% in 2016–2020), and 41% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
67 hospitals in 29 cities
Order: papers led on neuromyelitis optica spectrum disorder, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 2 papers or 1 trial on neuromyelitis optica spectrum disorder, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens neuromyelitis optica spectrum disorder in that city. 19 more cities are in the menu below.
- 39 papers led
- 36 papers ledNo open trial led
- 34 papers led
- 23 papers led
- 22 papers led
- 18 papers led
- 16 papers ledNo open trial led
- 12 papers led
- 11 papers ledNo open trial led
- 11 papers ledNo open trial led
- 11 papers led
- 10 papers ledNo open trial led
- 8 papers ledNo open trial led
- 8 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers ledNo open trial led
- 5 papers led
- 5 papers ledNo open trial led
- 5 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 36
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 51 papers led6 hospitals
- 46 papers led3 hospitals
- 36 papers led1 hospital
- 23 papers led2 hospitals
- 22 papers led1 hospital
- 19 papers led2 hospitals
- 17 papers led2 hospitals
- 15 papers led3 hospitals
- 14 papers led2 hospitals
- 14 papers led3 hospitals
- 12 papers led2 hospitals
- 12 papers led1 hospital
- 12 papers led2 hospitals
- 10 papers led2 hospitals
- 10 papers led2 hospitals
- 9 papers led2 hospitals
- 9 papers led2 hospitals
- 8 papers led2 hospitals
- 8 papers led2 hospitals
- 8 papers led4 hospitals
- 6 papers led1 hospital
- 6 papers led2 hospitals
- 5 papers led2 hospitals
- 5 papers led3 hospitals
- 4 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led1 hospital
- 3 papers led4 hospitals
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 1 paper led1 hospital
- 1 paper led0 hospitals
open trials on neuromyelitis optica spectrum disorder in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 28 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingA Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT05199688
Age 2 years to 11 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingTherapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
- Phase
- Phase 4
- Started
- 2026-02
- Registry
- NCT07410039
Age 18 years to 65 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingModified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07420296
Age 18 years to 80 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07526493
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07762872
Age 18 years to Not stated (registered criteria)
Led by Xuanwu HospitalBeijing
- RecruitingThe Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
- Phase
- Phase 1
- Started
- 2025-03
- Registry
- NCT06620809
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingProtein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06763848
Age 18 years to 65 years (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingHANDLE-a Real World Study on Satralizumab in NMOSD
- Phase
- Not given
- Started
- 2025-03
- Registry
- NCT06829524
Age 12 years to Not stated (registered criteria)
Led by Huashan HospitalShanghai
- RecruitingMonoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT06885957
Age 18 years to 65 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingUniversal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
- Phase
- Early phase 1
- Started
- 2025-06
- Registry
- NCT06939166
Age 18 years to Not stated (registered criteria)
Led by Tianjin Huanhu HospitalTianjin
- RecruitingSafety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT07022197
Age 18 years to 60 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingEfficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Phase
- N/A
- Started
- 2025-12
- Registry
- NCT07377305
Age 18 years to 75 years (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06249438
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
- RecruitingEfficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06474520
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingBiomarkers in Autoimmune Disease of Nervous System
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06502015
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingSun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06541626
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingCohort Study on Neuroimmune Diseases in the Reproductive Age
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT07653984
Age 20 years to 55 years; women only (registered criteria)
Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
- Phase
- Phase 2
- Started
- 2023-05
- Registry
- NCT06697535
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha
- RecruitingClinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- Phase
- Early phase 1
- Started
- 2022-04
- Registry
- NCT05145361
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Taiyuan, Tianjin, Xi'an
- RecruitingOfatumumab in AQP4-IgG Seropositive NMOSD
- Phase
- Phase 1/Phase 2
- Started
- 2022-06
- Registry
- NCT05504694
Age 18 years to Not stated (registered criteria)
Led by Tangdu HospitalXi'an
- RecruitingSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
- Phase
- Early phase 1
- Started
- 2020-09
- Registry
- NCT04561557
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingClinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
- Phase
- Not given
- Started
- 2019-01
- Registry
- NCT04106830
Age 16 years to 75 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- Not yet recruitingTongji NADs Cohort
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07333196
Age 18 years to 80 years (registered criteria)
Led by Tongji HospitalWuhan
- Not yet recruitingUniversal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune Diseases
- Phase
- Early phase 1
- Started
- 2026-03
- Registry
- NCT07392528
Age 18 years to Not stated (registered criteria)
Led by Tianjin Huanhu HospitalTianjin
- Not yet recruitingThe Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
- Phase
- Early phase 1
- Started
- 2026-05
- Registry
- NCT07592754
Age 18 years to 65 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07676266
Age 18 years to 70 years (registered criteria)
Led by Affiliated Hospital of Qingdao UniversityQingdao
- Not yet recruitingCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- Phase
- Phase 4
- Started
- 2026-06
- Registry
- NCT07699770
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an
- Not yet recruitingEfficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07809724
Age 18 years to 74 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingUniversal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
- Phase
- Early phase 1
- Started
- 2025-02
- Registry
- NCT06485232
Age 18 years to 75 years (registered criteria)
Led by Xuanwu HospitalBeijing
- Not yet recruitingProspective Cohort Study of Neuromyelitis Optica Spectrum Disorders (NMOSD)
- Phase
- Not given
- Started
- 2025-12
- Registry
- NCT07266051
Age 18 years to Not stated (registered criteria)
Led by Xiamen Hospital; 3 listed hospitals as study sitesShanghai, Xiamen
- Enrolling by invitationNormal Chinese Lifespan Brain Charts Initiative (NCLBCI)
- Phase
- Not given
- Started
- 2023-12
- Registry
- NCT06643858
Age 6 years to 90 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Rare disease diagnosis and treatment guideline (2019 edition), written for the first national rare-disease catalogueNational Health Commission 国卫办医函〔2019〕198号, 2019-02-27
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.